Introduction
Peripheral ischaemia is more common and severe among diabetic patients than among people who do not have diabetes [1, 2] . The clinical outcome, moreAbbreviations: DAPI, 4′-6′-diaminidino phenylindole · NGF, nerve growth factor · p75, P75 receptor of NGF · SCP/DAB, streptavidin-conjugated peroxidase · STZ, streptozotocin · TrkA, tyrosine kinase receptor-A of NGF · TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling · VEGF-A, vascular endothelial growth factor-A over, following vascular occlusion is uniquely poor in diabetic patients, as collateralisation is inadequate. An insufficient surge of vascular growth factors might contribute to the deficit [3] .
The neurotrophin nerve growth factor (NGF), initially recognised to be involved in nerve regeneration, also elicits a pro-angiogenic activity and promotes endothelial cell survival [4] and proliferation [5] . In skeletal muscles of non-diabetic mice, local expression of endogenous NGF and of its pro-angiogenic receptor tyrosine kinase receptor-A (TrkA) increases after blood flow is interrupted, and blockade of this native reaction results in severely compromised capillary growth in response to ischaemia [4] . Conversely, NGF supplementation accelerates tissue perfusion recovery by potentiating angiogenesis and arteriogenesis [4] .
We therefore hypothesised that this supply-side approach could have special therapeutic value in Type 1 diabetes mellitus. In fact, extensive previous studies have demonstrated that diabetes reduces the levels of NGF in several peripheral tissues, including nerves [6, 7, 8] and limb skeletal muscles [9] .
The objective of the present study was two-fold: (i) to investigate whether ischaemic limb muscles of Type 1 diabetic mice lack the ability to produce adequate amounts of NGF, and (ii) to investigate the therapeutic potential of exogenous NGF supplements for the treatment of ischaemic complications related to Type 1 diabetes.
Materials and methods
Induction and assessment of Type 1 diabetes. Procedures complied with the standards stated in the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Academy of Sciences, Bethesda, Md., USA 1996) and were in agreement with Italian law.
Type 1 diabetes was induced by streptozotocin (STZ) (40 mg/kg body weight i.p. daily for 5 consecutive days) in 2-month-old male CD1 mice (Charles River, Calco, Italy). In the majority of treated mice (around 85%) this procedure creates a moderate diabetic condition that allows them to survive for up to 4 months after treatment without receiving insulin supplementation [10] and without experiencing significant impairment of body weight gain in the first 2 months after STZ treatment (Emanueli et al., unpublished data) . Mice that had fasting glycaemia higher than 13.77 mmol/l and glycosuria at 14 days after the first STZ injection were considered diabetic. After this, urinary glucose levels were checked every 14 days, and only mice showing overt glycosuria on all occasions were included in the study. Body weight was recorded before STZ treatment and every 7 days thereafter. CD1 mice that were matched for age and sex and had not received STZ were used as non-diabetic controls. The body weight of non-diabetic control animals was recorded during the experimental period in the same way as in the Type 1 diabetic mice.
Induction of hindlimb ischaemia and nerve growth factor treatment. At 1 month from diabetes onset, mice were submitted to unilateral hindlimb ischaemia by electro-coagulation of the upper part of the left femoral artery. This was done under anaesthesia (2,2,2-tribromoethanol, 880 mmol/kg i.p., Sigma, Milan, Italy). Diabetic mice were randomly allocated to receive NGF (20 µg/20 µl per day into the ischaemic adductor muscle, n=10 mice) or its vehicle PBS (n=12). Treatments started on the day of surgery and were continued for the entire duration of the experiment (14 days). Non-diabetic control mice (n=8) underwent the same surgical procedure and received intramuscular PBS.
Nerve growth factor system expression in diabetic ischaemic muscles. A commercial ELISA kit (Promega, Milan, Italy) was used to determine NGF content in homogenates of ischaemic and contralateral adductor muscles removed 3 days after induction of ischaemia in Type 1 diabetic mice (n=8) or nondiabetic controls (n=7).
The expression of TrkA and P75 receptor of NGF (p75) in ischaemic and contralateral adductors was evaluated by immunohistochemistry at 14 days after surgery in Type 1 diabetic (n=4) and non-diabetic (n=5) mice. In addition, the effect of NGF supplementation or PBS on TrkA and p75 expression was determined in diabetic muscles (n=6 per group). To do this, anaesthetised mice were first perfused with heparinased PBS (1 min) and then with 10% buffered formalin (10 min) at 100 mm Hg via a cannula inserted into the abdominal aorta. Ischaemic and contralateral muscles were then removed and processed for paraffin embedding. TrkA identification was performed on 3-µm-thick muscular sections by using a polyclonal rabbit antibody (1:50, Santa Cruz, Santa Cruz, Calif., USA) diluted in PBS containing 1% normal goat serum. The specific binding was detected using a biotinylated anti-rabbit IgG and the streptavidin-peroxidase technique (Vectastain Elite ABC kit, Vector Laboratories, Burlingame, Calif., USA). P75 receptor was identified by using a monoclonal mouse antibody (1:50, DAKO, Carpinteria, Calif., USA) diluted in PBS containing 1% normal goat serum. Sections were incubated at the same time with primary and secondary antibody (DAKO), stained with streptavidin-conjugated peroxidase (SCP/DAB) and counterstained with haematoxylin. The primary antibody was not included in negative controls. Sections were evaluated at 1000×. In each field, the number of TrkA-positive endothelial cells, TrkA-positive myocytes, p75-positive endothelial cells and p75-positive myocytes was separately counted to compute their density per mm 2 of section. The number of TrkA-positive endothelial cells or p75-positive endothelial cells per 1000 capillaries was also calculated.
Effect of nerve growth factor supplementation on neovascularisation and apoptosis. We evaluated the microvascular density at 14 days after surgery in ischaemic and contralateral adductors of Type 1 diabetic mice receiving NGF or PBS. The same analysis was performed in muscles removed from PBS-treated non-diabetic controls. We cut 5-µm-thick sections from each sample with muscle fibres transversely oriented, and stained them with haematoxylin and eosin. Capillary and myofibre densities per mm 2 of muscular section were determined as previously described [10] . In addition, capillary density was normalised to myofibre density (n cap /n fiber ) [10] . Arteriole density per mm 2 of section area (n art /mm 2 ) was also calculated as described [10] .
Apoptosis was assessed by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling (TUNEL) assay in left and right adductors of NGF or PBS-treated Type 1 diabetic mice (n=5 for each group). Sections 3-µm-thick were stained with SCP/DAB and counterstained with haematoxylin. Negative controls were incubated in the absence of the terminal deoxynucleotidyl transferase. Sections were examined at 1000× magnification. TUNEL-positive endothelial cells and muscular cells were separately counted. The apoptotic rate was expressed as the number of TUNEL-positive cells per mm 2 of tissue. Apoptosis of endothelial cells was also computed as the number of apoptotic endothelial cells per 1000 capillaries.
Hindlimb blood flow measurements. Foot blood flow was measured at 30 min, 7 days, and 14 days after ischaemia using a perfusion imager system (Lisca, Linkoping, Sweden). The ischaemic : non-ischaemic foot blood flow ratio was calculated as an index of perfusion recovery [4] .
Evaluation of retinal vasculature of Type 1 diabetic mice receiving intramuscular NGF. In order to evaluate the possible occurrence of side effects similar to retinopathy in connection with NGF supplementation, we studied the retinal vasculature of Type 1 diabetic mice whose ischaemic limb muscles had been injected with NGF or PBS for 14 days (n=5 per group). Anaesthetised mice were perfusion-fixed through the heart and their eyes were removed, washed in PBS and fixed in 4% formalin. Mouse retinas were mounted flat on glass slides and the retinal vasculature was labelled with biotinylated Griffonia simplicifolia lectin B4 (Vector Laboratories), followed by Texas Red-conjugated Avidin D (Vector Laboratories) [11, 12] . The specimens were coded and four microscopic images were collected from both the central and peripheral region of each retina. Images were evaluated for signs of vascular pathology by two investigators blinded to the experimental treatment conditions.
Anti-apoptotic effect of nerve growth factor on cultured endothelial cells.
HUVECs were cultured in M199 with 20% FBS, 0.8% bovine brain extract (Clonetics, Walkersville, Md., USA) and antibiotics.
The effect of NGF on apoptosis induced by a combination of serum deprivation and high glucose was evaluated. To this aim, HUVECs prepared at our laboratory were re-suspended in full normoglycidic medium and seeded (10 4 cells per well) on to 12-well plates. After 24 h, the medium was changed into M199 containing 30 mmol/l D-glucose and 0.1% FBS. After an additional 2 h, NGF (100 ng/ml) or PBS was added and incubated for 24 h. The same experiment was repeated in the presence of an antibody (500 ng/ml) that neutralises vascular endothelial growth factor-A (VEGF-A) or control IgG.
Conditioned media were removed and stored at −20°C for subsequent assay, while attached cells were washed and fixed with 4% paraformaldehyde. Cells were labelled with 4′-6′-diaminidino phenylindole (DAPI) (100 ng/100 µl, Sigma), and apoptotic cells were identified on the basis of the appearance of nuclei with condensed and fragmented chromatin. DAPIstained cells were examined by fluorescent microscopy at 20×. In each well, five randomly selected fields were captured with a videocamera (Zeiss, Milan, Italy) and automatically analysed by Image Proplus software (Carlsbad, Calif., USA) for total cell number and apoptotic cell number. For each field, the percentage of apoptotic cells was calculated. This experiment was performed in quadruplicate and repeated three times.
Assay of vascular endothelial growth factor-A content in conditioned media of NGF-treated HUVECs.
The content of human VEGF-A in the conditioned media collected during the experiment described above was measured by a dedicated ELISA kit (human VEGF quantikine, R&D Systems, Minneapolis, Minn., USA).
Statistical analysis. Data are expressed as means ± SEM. Multivariate repeated-measures ANOVA was performed to test for interaction between treatments and groups. In multiple comparisons among independent groups in which ANOVA and the F test indicated significant differences the statistical value was determined according to Bonferroni's method. Differences within and between groups were determined using paired or unpaired Student's t tests respectively. A p value of less than 0.05 was considered to denote statistical significance.
Results
Expression of nerve growth factor receptor. No significant change in body weight was observed within each group during the study. Furthermore, at death, the body weight of the mice was similar in all groups (non-diabetic: 33.0±0.4 g; PBS-treated diabetic: 32.2±1.1 g; NGF-treated diabetic: 32.5±1.6 g; p=NS for all comparisons).
As shown in Figure 1 , diabetes reduced NGF content in ischaemic and normally perfused muscles.
We also found ( Nerve growth factor stimulates reparative angiogenesis. As expected, in PBS-injected ischaemic muscles of non-diabetic control mice, capillary and arteriole density was increased by 31 and 46% indicative of reparative neovascularisation (p<0.01 vs normally perfused contralateral muscles for both comparisons). By contrast, both capillary formation (Fig. 3a, b) and arteriogenesis (Fig. 4) were depressed in PBS-injected ischaemic diabetic muscles (p=NS vs contralaterals for both comparisons). However, a proper healing response was restored by daily injections of NGF. In fact, as shown in Figures 3a and 3b , NGF increased the capillary density of ischaemic muscles by 67% (1145±77 vs 684±76 cap/mm 2 in PBS-treated mice, p<0.001) and the capillary : myofibre ratio by 40% (1.4±0.1 vs 1.0±0.1 cap : fib in PBS-treated mice, p<0.01). Myofibre densitiy was not altered by NGF administration (data not shown). The therapeutic action of NGF was also evident (Fig. 4) at the level of the arterioles. In fact, NGF increased the density of arterioles in ischaemic muscles by 142% (13.6±2 vs 5.6±0.4 art/mm 2 in the PBS-treated group, p<0.01).
Nerve growth factor reduces apoptosis in diabetic ischaemic muscles. In diabetic ischaemic adductors, (Fig. 5a, b) ischaemia-induced increases in apoptotic death both of endothelial cells (p<0.01 vs normally perfused contralateral muscles) and of myofibres (p<0.05 vs normally perfused contralateral muscles). Apoptosis was reduced by NGF supplementation to diabetic ischaemic muscles (p<0.05 vs PBS-injected diabetic ischaemic muscles; p=NS vs non-diabetic ischaemic muscles). Figure 6 , NGF reversed the diabetes-induced impairment of post-ischaemic blood flow recovery (left : right foot perfusion ratio at 14 days: 0.81±0.12 vs 0.45±0.11 in PBS-treated Type 1 diabetic mice, p<0.05). The rate of perfusion recovery shown by NGF-treated Type 1 diabetic mice did not differ from that seen in non-diabetic control mice (p=NS at all the time points). Figure 7 , the retinal vasculature of mice treated with NGF was morphologically normal and indistinguishable from that in the control mice. There was no evidence of microaneurysms or neovascular growth.
Nerve growth factor improves the post-ischaemic perfusion recovery of Type 1 diabetic mice. As shown in

Administration of nerve growth factor into the ischaemic adductor muscles does not affect retinal vasculature of Type 1 diabetic mice. As shown by representative images in
Local administration of nerve growth factor reduces p75 receptor expression. We examined whether local supplementation with NGF alters the expression of NGF receptors in ischaemic muscles of Type 1 diabetic mice. We found that the number of p75-positive endo- NGF reduced the rate of apoptotic death of HUVECs, this effect being nullified by a neutralising antibody for VEGF-A (Fig. 8b) . Control IgG had no effect (data not shown).
Discussion
Our study shows that the expression of NGF and its p75 receptor in adductor skeletal muscles is influ- enced by Type 1 diabetes and that these changes are associated with impaired neovascularisation response to ischaemia and increased apoptosis. On the other hand, treatment with NGF tends to normalise the expressional pattern of p75, re-establishes reparative angiogenesis and arteriogenesis, and reduces apoptosis. Extensive previous works have demonstrated the production of NGF by neural tissues and unravelled the effects of NGF on the central and peripheral nervous system [13] . Emerging data suggest that NGF exerts pleiotropic effects in non-neural tissues. NGF production from vascular endothelial cells has also been demonstrated [5, 14] . In addition, NGF receptors are expressed on endothelial cells [4, 5, 14] , suggesting an autocrine/paracrine loop for the neurotrophininfluencing vascular physiology. NGF may also be directly implicated in the maintenance of proper skeletal muscle phenotype, as suggested by the severe muscular dystrophy produced by NGF phenotypic knockout in adult transgenic mice [15] .
Recently, we have shown that NGF acts as a potent stimulator of angiogenesis and exerts therapeutic effects on experimentally induced peripheral ischaemia in otherwise healthy mice [4] . The pro-angiogenic effect of NGF in vivo seems to be mediated by VEGF-A, as a neutralising antibody for VEGF-A inhibits the NGF-induced capillarisation response of ischaemic limb muscles [4] . Interestingly, Calza and colleagues have reported that NGF concomitantly increases VEGF-A expression and vascularity in the superior cervical ganglia of newborn rats [16] . The present study adds the new finding that under high-glucose conditions NGF stimulates human endothelial cells to produce/release VEGF-A. Moreover, we also document that the blockade of VEGF-A prevents the anti-apoptotic effect of NGF. Thus, NGF seemingly promotes cell survival via VEGF-A.
The importance of the present findings is that they indicate mutual interrelations between growth factors that control neurogenesis and angiogenesis. In vitro results are complemented by the information that NGF levels are decreased in ischaemic or contralateral adductors of Type 1 diabetic mice. NGF down-regulation might play a part in dampening the surge of VEGF-A in diabetic muscles [3] or sciatic nerves [17] subjected to ischaemia. Altogether, the above deficiencies could account for the more complicated clinical outcome observed after arterial occlusion in Type 1 diabetic mice.
NGF exerts its biological action through the contribution of two receptors: the high-affinity TrkA and the low-affinity p75 [18] . In endothelial cells, NGF-mediated TrkA phosphorylation activates the mitogen-activated protein kinase pathway and leads to cell proliferation [5] . The role and signalling pathway of p75 are still controversial. The receptor has been linked to apoptosis of vascular smooth muscle cells [19] , neurons and oligodendrocytes [20] , although consensus on this theory is not universal [21] . Our study is the first to propose a correlation between p75 and apoptotic death of endothelial cells, and to indicate a possible implication of p75 in diabetic microangiopathy. Up-regulation of the receptor may be a hallmark of death for diabetic tissues subjected to ischaemic insult (as shown here) or to mechanical cutaneous injury (see article by Graiani et al. in this issue of Diabetologia). The large up-regulation of p75 in endothelial cells, which occurred concomitantly with reduced NGF in the ischaemic limb muscles of Type 1 diabetic mice, may lead to an excess of p75 not occupied by their ligand. A similar scenario has been implicated by some authors in the generation of apoptotic signals in neurons [22, 23, 24, 25] . Moreover, the interaction between NGF and TrkA, as well as post-receptorial TrkA signalling, may be affected by reduced NGF and increased p75 expression. Additional work will be necessary to clarify whether p75 has a direct proapoptotic effect on endothelial cells and to identify the molecular signalling that leads to activation of p75 in diabetic endothelial cells.
Most importantly, in a diabetic mouse model with superimposed ischaemia, we demonstrated that NGF supplementation stimulates reparative neovascularisation, improves blood flow recovery and concomitantly decreases the number of p75-positive endothelial cells and apoptosis. Interestingly, with regard to possible clinical exploitation, repeated local administration of NGF into ischaemic limbs did not endanger the retina of mice. This is not a secondary issue, as it is well known that abnormal capillarisation causes retinopathy, one of the most diffuse and severe complications of diabetes. Moreover, we did not observe any evident signs of abnormal behaviour connected to increased pain perception in NGF-treated mice.
In conclusion, our study suggests that NGF may represent a potential new therapeutic tool to combat microvascular complications caused by diabetes.
